Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir + Kivexa versus Atripla in treatment-naive adults with HIV-1
NL-OMON38393Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dolutegravir, abacavir, lamivudine, efavirenz, emtricitabine and 1 more in human immunodeficiency virus infection (HIV) (2 arms), sponsored by GSK. Primary endpoint: Proportion of subjects with HIV-1 RNA <50 copies/mL at week 48. Started Apr 2011; status: active, not recruiting.
02
Drugs
dolutegravirabacavirlamivudineefavirenzemtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON38393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38393.